To the Editor: I wish to bring to the attention of your readers a potentially misleading abstract in the study by T.R. Pedersen on the six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction (Oct. 24 issue).* Pedersen et al. state in their abstract: “We conclude that the previously observed early beneficial effect of beta-adrenergic blocking therapy is maintained for at least six years after infarction.” In their careful and informative discussion, however, the authors cautiously state: “In the meantime, the present analysis shows no harmful effect, and possibly a continued benefit, from long-term treatment with…, No extract is available for articles shorter than 400 words.
ASJC Scopus subject areas